Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
NCT ID: NCT05732623
Last Updated: 2024-11-29
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
2300 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-12-05
Study Completion Date
2035-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally.
CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants, obesity, alcohol, physical activity, red meat, and a Western diet).
Design: an international, multicenter, retrospective case-control study of prospectively enrolled patients; low-risk intervention study as it will perform a fecal occult blood test Endpoint: predictive power of a semi-quantitative food frequency questionnaire (SQFFQ) developed for eoCRC.
Cases: Patients with a recent diagnosis of eoCRC (within 2 years from enrollment).
Controls: matched by age (matching range ± 5 years) and sex. Healthy volunteers will be mainly enrolled among workers within the participating hospital center. The enrolled healthy volunteers will perform a fecal occult blood test.
Variables of interest: age, sex, ethnicity, BMI at the time of eoCRC diagnosis and at 18 years old, country, tobacco smoking at the time of eoCRC diagnosis and at 18 years old, sitting time, TV-viewing time, moderate-to-vigorous physical activity (MVPA), waist circumference (cm), home blood pressure levels (mmHg), fasting blood glucose (mg/dl), regular consumption of aspirin/NSAID, calcium and folate supplements, oral contraceptive agents, post-menopausal hormones and years of consumptions, if the filled questionnaire reflects diet for the last 5-10 years before.
Cases only: date of eoCRC diagnosis, symptoms at diagnosis, eoCRC localization, eoCRC stage, histological diagnosis, type of surgery, and date (if performed), chemotherapy and radiotherapy (if performed), vital status and duration of follow-up, family history of CRC and other cancers (uterus, ovary, stomach, small intestine, urinary tract/bladder/kidney, bile ducts, brain, pancreas, skin tumors), type of germline pathogenetic variant (if performed).
Before the case-control study, three non-consecutive 24-hour Dietary Recalls (24hDRs) will validate the SQFFQ.
The SQFFQ will be administered to the validation study group during three non-consecutive calls, including one non-weekday (30-minute 24-h-recall computer-aided personal interview).
Primary Objective To measure the relative risk of specific dietary and lifestyle factors (smoking habit, alcohol intake, physical activity) for early-onset colorectal cancer in countries where eoCRC incidence is increasing versus stable/decreasing
CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants, obesity, alcohol, physical activity, red meat, and a Western diet).
Design: an international, multicenter, retrospective case-control study of prospectively enrolled patients; low-risk intervention study as it will perform a fecal occult blood test Endpoint: predictive power of a semi-quantitative food frequency questionnaire (SQFFQ) developed for eoCRC.
Cases: Patients with a recent diagnosis of eoCRC (within 2 years from enrollment).
Controls: matched by age (matching range ± 5 years) and sex. Healthy volunteers will be mainly enrolled among workers within the participating hospital center. The enrolled healthy volunteers will perform a fecal occult blood test.
Variables of interest: age, sex, ethnicity, BMI at the time of eoCRC diagnosis and at 18 years old, country, tobacco smoking at the time of eoCRC diagnosis and at 18 years old, sitting time, TV-viewing time, moderate-to-vigorous physical activity (MVPA), waist circumference (cm), home blood pressure levels (mmHg), fasting blood glucose (mg/dl), regular consumption of aspirin/NSAID, calcium and folate supplements, oral contraceptive agents, post-menopausal hormones and years of consumptions, if the filled questionnaire reflects diet for the last 5-10 years before.
Cases only: date of eoCRC diagnosis, symptoms at diagnosis, eoCRC localization, eoCRC stage, histological diagnosis, type of surgery, and date (if performed), chemotherapy and radiotherapy (if performed), vital status and duration of follow-up, family history of CRC and other cancers (uterus, ovary, stomach, small intestine, urinary tract/bladder/kidney, bile ducts, brain, pancreas, skin tumors), type of germline pathogenetic variant (if performed).
Before the case-control study, three non-consecutive 24-hour Dietary Recalls (24hDRs) will validate the SQFFQ.
The SQFFQ will be administered to the validation study group during three non-consecutive calls, including one non-weekday (30-minute 24-h-recall computer-aided personal interview).
Primary Objective To measure the relative risk of specific dietary and lifestyle factors (smoking habit, alcohol intake, physical activity) for early-onset colorectal cancer in countries where eoCRC incidence is increasing versus stable/decreasing
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background Firstly described in U.S. series, an increase in early-onset colorectal cancers (eoCRC), defined as CRC before 50 years, is confirmed globally.
CRC pathogenesis has been associated with several endogenous and exogenous associated risk factors, including family history of CRC, CRC-related germline pathogenic variants, obesity, alcohol habits, physical activity, red and processed meat and a Western diet. Two dietary patterns appear as exogenous and behavioral factors associated with either CRC prevention or predisposition: the 'healthy' pattern (high in fruits, vegetables, and whole grains or legumes, fish, and low-fat milk or dairy products) and the 'unhealthy' or 'Western dietary' pattern (high in red and processed meat, sugary drinks, refined grains, desserts). Above all, the Western diet is one of the most important CRC risk factors. In the Nurses' Health Study II, Western diet during adolescence was associated with the development of high-risk rectal adenomas later in life. In a meta-analysis of cohort studies, the Western dietary pattern conferred a relative risk (RR) of 1.12 for CRC, compared with a 0.89 RR for the healthy pattern. Conversely, the Mediterranean diet demonstrated a protective role in CRC development, confirmed in the EPIC cohort study.
Rationale Dietary, lifestyle, and anthropometric risk factors are still poorly understood in eoCRC patients, despite its established rising incidence. To date, scant studies, mostly case-control and only a few prospective ones, investigated the exogenous risk factors of eoCRCs and eoCRC precursors and identified high intake of alcohol and processed meat, sedentary lifestyle as potential eoCRC risk factors, and obesity as ambiguous one.
Primary Objective To compare the associations of specific dietary and lifestyle factors (smoking habit, alcohol intake, physical activity) and anthropometric factors between eoCRC patients and healthy age- and sex-matched controls in countries with increasing versus stable or decreasing early-onset colorectal cancer (eoCRC) incidence.
Secondary Objectives
1. To validate the semi-quantitative food frequency questionnaire (SQFFQ);
2. To evaluate the consistency of associations across cohorts in pairwise comparisons;
3. To assess whether associations differ among specific population subgroups (e.g., sex, ethnicity, smoking habits, BMI, physical activity, family history of CRC).
Type of study SQFFQ validation study: three non-consecutive 24-hour Dietary Recalls (24hDRs) will validate the ad hoc designed and shared SQFFQ, as previously performed \[28-29\]. The SQFFQ will be administered to the validation study group during three non-consecutive calls, including one non-weekday (30 minutes 24-h-recall computer-aided personal interview).
Case-control study: an international, multicentre, retrospective case-control study of prospectively enrolled patients will be performed to evaluate the associations of dietary, anthropometric, lifestyle factors in eoCRC patients compared to age, and sex matched healthy controls.
This study is sub-classified as a low-risk intervention study as it will perform fecal occult blood test as an additional procedure in the control group.
Inclusion criteria All sexes eligible Cases: eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery) Controls: negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.
Exclusion criteria CRC diagnosed at ≥ 50 years Diseases that can modify the dietary regimen (celiac disease, diabetes) Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation) Unable to give written consents and to fill in the electronic questionnaire
Sample size
SQFFQ Validation study:
\- 100 subjects from each country, free from overt disease and in equal numbers of each gender.
Case-control study:
* At least 300 eoCRC patients in total;
* At least 600 healthy age- (matching range ± 5 years) and sex-matched controls subjects in total.
Study Procedure and Study Flow-chart Starting from the signature of the informed consent by the subject/patient (or subject/patient's legal tutor), she/he will be considered enrolled in the study.
The PI will be the only Administrator of the online platform and the only one able to generate the access codes (username/password) assigned to the co-investigators.
Each co-investigator will register the enrolled subjects anonymously on the online platform (unique alphanumeric identification code - see below), obtaining a username/password assigned to the subject for survey completion.
The unique alphanumeric identification code (Subject ID number) will be assigned consecutively in increasing order starting from '001'. A screened subject/patient identification list will be kept by PI.
SQFFQ validation study:
One hundred volunteers from each country, free from overt disease and in equal numbers of each sex, will be enrolled for the semi-quantitative food frequency questionnaire (SQFFQ) validation study. Potential volunteers will be recruited through different recruitment strategies: mail drops, recruitment lists, and databases, primary care facilities as well as networks for young people and/or among people who work in the same hospital of the research team, regularly followed by preventive medicine.
An ad hoc-designed and shared online SQFFQ will be available to report the usual frequency of consumption of a detailed list of foods and beverages. Information collected concern types, amount and frequency of consumption of food and drinks, types of seasoning, and methods of cooking. The computer-administered instrument will allow the respondent to select the food consumed and the appropriate portion size from photographs on a screen reducing the burden of coding.
All volunteers will receive detailed oral and written information by members of the study team (following local practices).
Three non-consecutive 24-hour Dietary Recalls (24hDRs), including one non-weekday (30 minutes 24-h-recall computer-aided personal interview), will validate the SQFFQ \[28-29\].
Case-control study:
An international, multicentre, retrospective case-control study of prospectively enrolled patients will be performed to evaluate the associations of dietary, anthropometric, lifestyle factors in eoCRC patients compared to age, and sex matched healthy controls.
This study is sub-classified as a low-risk intervention study as it will perform fecal occult blood test as an additional procedure in the control group.
The study will recruit:
* at least 300 patients in total (100 at IRCCS San Raffaele Scientific Institute) with a recent diagnosis of eoCRC (diagnosis made within 2 years prior to enrollment), aged 18-49 years, will be prospectively recruited. eoCRC patients will be primarily enrolled as referred by the participant unit. Each participant unit shall identify eoCRC patients through recruitment lists and databases, primary care facilities, as well as networks for young people. Retrospective data (dietary and lifestyle factors) related to the 2 years prior to eoCRC diagnosis will be collected through an online platform.
* at least 600 Healthy controls (HCs) totally (200 at IRCCS San Raffaele Scientific Institute), matched by age (matching range ± 5 years) and sex with eoCRCs will be prospectively enrolled. Healthy volunteers will be mainly enrolled among workers within the participating hospital center, followed regularly by preventive medicine. This enrollment will be carried out by e-mail invitation disseminated through the hospital's official mailing list. The enrolled healthy volunteers will perform fecal occult blood test as an additional procedure and will be enrolled if this test is negative. Retrospective data (dietary and lifestyle factors) related to the 2 years prior to recruitment will be collected through an online platform.
The online platform will be divided into two separate sections: (i) one completed by cases / controls, concerning the semi-quantitative food frequency questionnaire (SQFFQ), lifestyle habits and anthropometric data; (ii) one completed by doctors, concerning clinical data.
The semi-quantitative food frequency approach will ask to report their usual frequency of consumption of each food and drink, referred to the two years before eoCRC onset, following detailed oral and written instructions from the members of the study team. Information collected will concern types, amount and frequency of consumption of food and drinks, types of seasoning, and methods of cooking. A computer-administered instrument will allow the respondent to select the food consumed and the appropriate portion size from photographs on a screen reducing the burden of coding.
All cases and healthy controls will also provide a set of covariates as part of the online platform: date of birth, sex, ethnicity, weight (kg)/height (m)/BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old, country where the patient/healthy control lives permanently, tobacco smoking at the time of eoCRC diagnosis and at 18 years old, sitting time, TV-viewing time, moderate-to-vigorous physical activity (MVPA), waist circumference (cm), home blood pressure levels (mmHg), fasting blood glucose (mg/dl), regular consumption of aspirin/NSAID, calcium and folate supplements, oral contraceptive agents, post-menopausal hormones and years of consumptions, if the filled questionnaire reflects diet for the last 5-10 years before.
Other clinical data will be collected by doctors as part of the online platform: date of eoCRC diagnosis, symptoms at diagnosis, eoCRC localization, eoCRC stage, histological diagnosis, type of surgery and date (if performed), chemoterapy and radiotherapy (if performed), vital status and duration of follow-up, family history of CRC and other cancers (uterus, ovary, stomach, small intestine, urinary tract/bladder/kidney, bile ducts, brain, pancreas, skin tumors), type of germline pathogenetic variant (if performed).
4.6 Responsibilities of the Investigator(s) The Investigator(s) undertake(s) to perform the study in accordance with this Protocol, Good Clinical Practice and the applicable regulatory requirements.
The Investigator is required to ensure compliance with the investigational schedule, and procedures required by the protocol.
The Investigator agrees to provide all information requested in the Case Report Form -CRF- in an accurate and legible manner.
ETHICAL CONSIDERATIONS Ethical conduct of the study The study will be performed according the ethical principles laid down in the latest accepted version of the Declaration of Helsinki.
Patient information and informed consent Each subject/patient will be informed about the modalities of the clinical study in accordance with the enclosed patient information. The subject/patient is to be informed both in writing and verbally by the investigating physician. The subject/patient must be given opportunity to decide whether or not to participate in this study and to ask questions concerning this. It must also be made clear to the subject/patient that he/she can withdraw from the study at any time without giving reasons and that he/she will not be in any way disadvantaged by this. The points mentioned in the information sheet must be communicated to the patient in language he/she understands. The informing physician and the patient must each personally date and sign an informed consent form with a declaration on data privacy. Any informed consent will be part of the investigator's file and retained with it. The subject/patient will retain a copy of the patient information.
Data management The personal data will be recorded in the electronic CRF designed for this study. All CRF will be checked for completeness, plausibility, and compliance with the ICH guidelines and the institutional Standard Operating Procedures (SOPs).
The personal data will be identified with a code (see section 6.7) not allowing directly trace the identity of the patients/individuals, except in case of need. In all phases of collection and processing of personal data, suitable measures will be adopted to guarantee their protection from the risks of unauthorized access, theft or loss, also through the use of encryption techniques, identification codes or other solutions that allow identify the interested parties only in case of need and to those who are expressly authorized to access them, in order to minimize the risks of accidental knowledge and unauthorized or abusive access to data. The genetic and clinical data of the interested parties are, however, treated separately from other "common" personal data (name, surname, etc.), which allow the interested parties to be directly identified.
The collection, management and analysis of data will take place in a way that guarantees the confidentiality of the subject's identity and will follow the General Data Protection Regulations (GDPR).
With regard to the possible transfer of data to third countries, the processing will take place according to one of the methods permitted by current law, such as the consent given by the patients/individuals, the adoption of Standard Clauses approved by the European Commission, the selection of subjects adhering to international programs for the free circulation of data (eg EU-USA Privacy Shield) or operating in countries considered safe by the European Commission.
All analyses will be performed within respective limitations of each ethics committee approval and in accordance with good clinical practice and the Declaration of Helsinki.
Sample size
SQFFQ Validation study:
100 subjects from each country, free from overt disease and in equal numbers of each gender.
Case-control study:
Power analysis for odds ratios calculation The odds ratios of eoCRC for different exposition factors will be calculated.
For this purpose, a power analysis is performed, based on the following parameters:
* Significance level (alpha, 1 type error probability) = 0.05 (two tails test)
* Power of the analysis = 80%
* Number of controls per case = 2
* Minimum Odds Ratio to detect = 2
* Proportion of exposed in the general population The proportion of exposed individuals in the general population depends on the considered exposition factors (such as a specific diet habit, alcohol consumption, etc.): for this reason, the sample size was calculated for different exposition proportions, varying from 5% to 95%.
Statistical analysis
SQFFQ validation Study:
The validity of the SQFFQ will be computed by calculating the Spearman correlation coefficients between individual food groups intakes from SQFFQ and the average of three 24hDR food groups intakes as the reference method.
The percentage of the agreement as the proportions of individuals who were classified correctly into the same or adjacent quintile for validity analyses will be calculated.
Case-control Study:
In the case-control study, an association between eoCRC and dietary habits (or other exposition factors such as alcohol consumption, smoking habits, etc.) will be estimated using logistic regression and odds ratio calculation. Multivariate logistic regression models will be used to examine to what extent eoCRC development can be 'explained' by variations in eating habits. The stratified analysis will also be performed by considering only a specific gender and/or other grouping variables of interest such as age, age at diagnosis. The effects of potential confounders other than matching criteria (e.g., smoking, physical activity, etc.) will also be estimated and taken into account. All analyses are based on a conservative estimate of eoCRC cancer cases, with at least 2 controls per case.
CRC pathogenesis has been associated with several endogenous and exogenous associated risk factors, including family history of CRC, CRC-related germline pathogenic variants, obesity, alcohol habits, physical activity, red and processed meat and a Western diet. Two dietary patterns appear as exogenous and behavioral factors associated with either CRC prevention or predisposition: the 'healthy' pattern (high in fruits, vegetables, and whole grains or legumes, fish, and low-fat milk or dairy products) and the 'unhealthy' or 'Western dietary' pattern (high in red and processed meat, sugary drinks, refined grains, desserts). Above all, the Western diet is one of the most important CRC risk factors. In the Nurses' Health Study II, Western diet during adolescence was associated with the development of high-risk rectal adenomas later in life. In a meta-analysis of cohort studies, the Western dietary pattern conferred a relative risk (RR) of 1.12 for CRC, compared with a 0.89 RR for the healthy pattern. Conversely, the Mediterranean diet demonstrated a protective role in CRC development, confirmed in the EPIC cohort study.
Rationale Dietary, lifestyle, and anthropometric risk factors are still poorly understood in eoCRC patients, despite its established rising incidence. To date, scant studies, mostly case-control and only a few prospective ones, investigated the exogenous risk factors of eoCRCs and eoCRC precursors and identified high intake of alcohol and processed meat, sedentary lifestyle as potential eoCRC risk factors, and obesity as ambiguous one.
Primary Objective To compare the associations of specific dietary and lifestyle factors (smoking habit, alcohol intake, physical activity) and anthropometric factors between eoCRC patients and healthy age- and sex-matched controls in countries with increasing versus stable or decreasing early-onset colorectal cancer (eoCRC) incidence.
Secondary Objectives
1. To validate the semi-quantitative food frequency questionnaire (SQFFQ);
2. To evaluate the consistency of associations across cohorts in pairwise comparisons;
3. To assess whether associations differ among specific population subgroups (e.g., sex, ethnicity, smoking habits, BMI, physical activity, family history of CRC).
Type of study SQFFQ validation study: three non-consecutive 24-hour Dietary Recalls (24hDRs) will validate the ad hoc designed and shared SQFFQ, as previously performed \[28-29\]. The SQFFQ will be administered to the validation study group during three non-consecutive calls, including one non-weekday (30 minutes 24-h-recall computer-aided personal interview).
Case-control study: an international, multicentre, retrospective case-control study of prospectively enrolled patients will be performed to evaluate the associations of dietary, anthropometric, lifestyle factors in eoCRC patients compared to age, and sex matched healthy controls.
This study is sub-classified as a low-risk intervention study as it will perform fecal occult blood test as an additional procedure in the control group.
Inclusion criteria All sexes eligible Cases: eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery) Controls: negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.
Exclusion criteria CRC diagnosed at ≥ 50 years Diseases that can modify the dietary regimen (celiac disease, diabetes) Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation) Unable to give written consents and to fill in the electronic questionnaire
Sample size
SQFFQ Validation study:
\- 100 subjects from each country, free from overt disease and in equal numbers of each gender.
Case-control study:
* At least 300 eoCRC patients in total;
* At least 600 healthy age- (matching range ± 5 years) and sex-matched controls subjects in total.
Study Procedure and Study Flow-chart Starting from the signature of the informed consent by the subject/patient (or subject/patient's legal tutor), she/he will be considered enrolled in the study.
The PI will be the only Administrator of the online platform and the only one able to generate the access codes (username/password) assigned to the co-investigators.
Each co-investigator will register the enrolled subjects anonymously on the online platform (unique alphanumeric identification code - see below), obtaining a username/password assigned to the subject for survey completion.
The unique alphanumeric identification code (Subject ID number) will be assigned consecutively in increasing order starting from '001'. A screened subject/patient identification list will be kept by PI.
SQFFQ validation study:
One hundred volunteers from each country, free from overt disease and in equal numbers of each sex, will be enrolled for the semi-quantitative food frequency questionnaire (SQFFQ) validation study. Potential volunteers will be recruited through different recruitment strategies: mail drops, recruitment lists, and databases, primary care facilities as well as networks for young people and/or among people who work in the same hospital of the research team, regularly followed by preventive medicine.
An ad hoc-designed and shared online SQFFQ will be available to report the usual frequency of consumption of a detailed list of foods and beverages. Information collected concern types, amount and frequency of consumption of food and drinks, types of seasoning, and methods of cooking. The computer-administered instrument will allow the respondent to select the food consumed and the appropriate portion size from photographs on a screen reducing the burden of coding.
All volunteers will receive detailed oral and written information by members of the study team (following local practices).
Three non-consecutive 24-hour Dietary Recalls (24hDRs), including one non-weekday (30 minutes 24-h-recall computer-aided personal interview), will validate the SQFFQ \[28-29\].
Case-control study:
An international, multicentre, retrospective case-control study of prospectively enrolled patients will be performed to evaluate the associations of dietary, anthropometric, lifestyle factors in eoCRC patients compared to age, and sex matched healthy controls.
This study is sub-classified as a low-risk intervention study as it will perform fecal occult blood test as an additional procedure in the control group.
The study will recruit:
* at least 300 patients in total (100 at IRCCS San Raffaele Scientific Institute) with a recent diagnosis of eoCRC (diagnosis made within 2 years prior to enrollment), aged 18-49 years, will be prospectively recruited. eoCRC patients will be primarily enrolled as referred by the participant unit. Each participant unit shall identify eoCRC patients through recruitment lists and databases, primary care facilities, as well as networks for young people. Retrospective data (dietary and lifestyle factors) related to the 2 years prior to eoCRC diagnosis will be collected through an online platform.
* at least 600 Healthy controls (HCs) totally (200 at IRCCS San Raffaele Scientific Institute), matched by age (matching range ± 5 years) and sex with eoCRCs will be prospectively enrolled. Healthy volunteers will be mainly enrolled among workers within the participating hospital center, followed regularly by preventive medicine. This enrollment will be carried out by e-mail invitation disseminated through the hospital's official mailing list. The enrolled healthy volunteers will perform fecal occult blood test as an additional procedure and will be enrolled if this test is negative. Retrospective data (dietary and lifestyle factors) related to the 2 years prior to recruitment will be collected through an online platform.
The online platform will be divided into two separate sections: (i) one completed by cases / controls, concerning the semi-quantitative food frequency questionnaire (SQFFQ), lifestyle habits and anthropometric data; (ii) one completed by doctors, concerning clinical data.
The semi-quantitative food frequency approach will ask to report their usual frequency of consumption of each food and drink, referred to the two years before eoCRC onset, following detailed oral and written instructions from the members of the study team. Information collected will concern types, amount and frequency of consumption of food and drinks, types of seasoning, and methods of cooking. A computer-administered instrument will allow the respondent to select the food consumed and the appropriate portion size from photographs on a screen reducing the burden of coding.
All cases and healthy controls will also provide a set of covariates as part of the online platform: date of birth, sex, ethnicity, weight (kg)/height (m)/BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old, country where the patient/healthy control lives permanently, tobacco smoking at the time of eoCRC diagnosis and at 18 years old, sitting time, TV-viewing time, moderate-to-vigorous physical activity (MVPA), waist circumference (cm), home blood pressure levels (mmHg), fasting blood glucose (mg/dl), regular consumption of aspirin/NSAID, calcium and folate supplements, oral contraceptive agents, post-menopausal hormones and years of consumptions, if the filled questionnaire reflects diet for the last 5-10 years before.
Other clinical data will be collected by doctors as part of the online platform: date of eoCRC diagnosis, symptoms at diagnosis, eoCRC localization, eoCRC stage, histological diagnosis, type of surgery and date (if performed), chemoterapy and radiotherapy (if performed), vital status and duration of follow-up, family history of CRC and other cancers (uterus, ovary, stomach, small intestine, urinary tract/bladder/kidney, bile ducts, brain, pancreas, skin tumors), type of germline pathogenetic variant (if performed).
4.6 Responsibilities of the Investigator(s) The Investigator(s) undertake(s) to perform the study in accordance with this Protocol, Good Clinical Practice and the applicable regulatory requirements.
The Investigator is required to ensure compliance with the investigational schedule, and procedures required by the protocol.
The Investigator agrees to provide all information requested in the Case Report Form -CRF- in an accurate and legible manner.
ETHICAL CONSIDERATIONS Ethical conduct of the study The study will be performed according the ethical principles laid down in the latest accepted version of the Declaration of Helsinki.
Patient information and informed consent Each subject/patient will be informed about the modalities of the clinical study in accordance with the enclosed patient information. The subject/patient is to be informed both in writing and verbally by the investigating physician. The subject/patient must be given opportunity to decide whether or not to participate in this study and to ask questions concerning this. It must also be made clear to the subject/patient that he/she can withdraw from the study at any time without giving reasons and that he/she will not be in any way disadvantaged by this. The points mentioned in the information sheet must be communicated to the patient in language he/she understands. The informing physician and the patient must each personally date and sign an informed consent form with a declaration on data privacy. Any informed consent will be part of the investigator's file and retained with it. The subject/patient will retain a copy of the patient information.
Data management The personal data will be recorded in the electronic CRF designed for this study. All CRF will be checked for completeness, plausibility, and compliance with the ICH guidelines and the institutional Standard Operating Procedures (SOPs).
The personal data will be identified with a code (see section 6.7) not allowing directly trace the identity of the patients/individuals, except in case of need. In all phases of collection and processing of personal data, suitable measures will be adopted to guarantee their protection from the risks of unauthorized access, theft or loss, also through the use of encryption techniques, identification codes or other solutions that allow identify the interested parties only in case of need and to those who are expressly authorized to access them, in order to minimize the risks of accidental knowledge and unauthorized or abusive access to data. The genetic and clinical data of the interested parties are, however, treated separately from other "common" personal data (name, surname, etc.), which allow the interested parties to be directly identified.
The collection, management and analysis of data will take place in a way that guarantees the confidentiality of the subject's identity and will follow the General Data Protection Regulations (GDPR).
With regard to the possible transfer of data to third countries, the processing will take place according to one of the methods permitted by current law, such as the consent given by the patients/individuals, the adoption of Standard Clauses approved by the European Commission, the selection of subjects adhering to international programs for the free circulation of data (eg EU-USA Privacy Shield) or operating in countries considered safe by the European Commission.
All analyses will be performed within respective limitations of each ethics committee approval and in accordance with good clinical practice and the Declaration of Helsinki.
Sample size
SQFFQ Validation study:
100 subjects from each country, free from overt disease and in equal numbers of each gender.
Case-control study:
Power analysis for odds ratios calculation The odds ratios of eoCRC for different exposition factors will be calculated.
For this purpose, a power analysis is performed, based on the following parameters:
* Significance level (alpha, 1 type error probability) = 0.05 (two tails test)
* Power of the analysis = 80%
* Number of controls per case = 2
* Minimum Odds Ratio to detect = 2
* Proportion of exposed in the general population The proportion of exposed individuals in the general population depends on the considered exposition factors (such as a specific diet habit, alcohol consumption, etc.): for this reason, the sample size was calculated for different exposition proportions, varying from 5% to 95%.
Statistical analysis
SQFFQ validation Study:
The validity of the SQFFQ will be computed by calculating the Spearman correlation coefficients between individual food groups intakes from SQFFQ and the average of three 24hDR food groups intakes as the reference method.
The percentage of the agreement as the proportions of individuals who were classified correctly into the same or adjacent quintile for validity analyses will be calculated.
Case-control Study:
In the case-control study, an association between eoCRC and dietary habits (or other exposition factors such as alcohol consumption, smoking habits, etc.) will be estimated using logistic regression and odds ratio calculation. Multivariate logistic regression models will be used to examine to what extent eoCRC development can be 'explained' by variations in eating habits. The stratified analysis will also be performed by considering only a specific gender and/or other grouping variables of interest such as age, age at diagnosis. The effects of potential confounders other than matching criteria (e.g., smoking, physical activity, etc.) will also be estimated and taken into account. All analyses are based on a conservative estimate of eoCRC cancer cases, with at least 2 controls per case.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Colorectal Cancer
Early Onset Colorectal Cancer
Diet Habit
Risk Reduction
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early onset colorectal cancer
Patients with colorectal cancer diagnosed before the age of 50 years
Semi Quantitative Food Frequency Questionnaire (SQFFQ)
Intervention Type
BEHAVIORAL
The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:
* date of birth
* sex
* ethnicity
* weight (kg)
* height (m)
* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old
* country where they live permanently
* tobacco smoking at the time of eoCRC diagnosis and at 18 years old
* sitting time
* TV-viewing time
* moderate-to-vigorous physical activity (MVPA)
* waist circumference (cm)
* home blood pressure levels (mmHg)
* fasting blood glucose (mg/dl)
* regular consumption of aspirin/NSAID and years of consumptions
* calcium and folate supplements and years of consumptions
* oral contraceptive agents and years of consumptions
* post-menopausal hormones and years of consumptions
Control
Individuals meeting all the following:
* aged \<50 years
* no history of colorectal cancer
* at least one negative screening test (at least a fecal occult blood test with high sensitivity)
Semi Quantitative Food Frequency Questionnaire (SQFFQ)
Intervention Type
BEHAVIORAL
The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:
* date of birth
* sex
* ethnicity
* weight (kg)
* height (m)
* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old
* country where they live permanently
* tobacco smoking at the time of eoCRC diagnosis and at 18 years old
* sitting time
* TV-viewing time
* moderate-to-vigorous physical activity (MVPA)
* waist circumference (cm)
* home blood pressure levels (mmHg)
* fasting blood glucose (mg/dl)
* regular consumption of aspirin/NSAID and years of consumptions
* calcium and folate supplements and years of consumptions
* oral contraceptive agents and years of consumptions
* post-menopausal hormones and years of consumptions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Semi Quantitative Food Frequency Questionnaire (SQFFQ)
The SQFFQ quantifies the frequency of consumption of each food and drink and the following list of variables:
* date of birth
* sex
* ethnicity
* weight (kg)
* height (m)
* BMI (kg/m2) at the time of eoCRC diagnosis and at 18 years old
* country where they live permanently
* tobacco smoking at the time of eoCRC diagnosis and at 18 years old
* sitting time
* TV-viewing time
* moderate-to-vigorous physical activity (MVPA)
* waist circumference (cm)
* home blood pressure levels (mmHg)
* fasting blood glucose (mg/dl)
* regular consumption of aspirin/NSAID and years of consumptions
* calcium and folate supplements and years of consumptions
* oral contraceptive agents and years of consumptions
* post-menopausal hormones and years of consumptions
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All sexes eligible
* (for Cases) eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery)
* (for Controls) negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.
* (for Cases) eoCRC diagnosed between 18 and 49 years and confirmed by histology (biopsy or surgical specimen in case of surgery)
* (for Controls) negative past and present history of cancer; negative fecal occult blood test (FOBT), or negative colonoscopy.
Exclusion Criteria
* CRC diagnosed at ≥ 50 years
* Diseases that can modify the dietary regimen (celiac disease, diabetes)
* Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation)
* Unable to give written consents and to fill in the electronic questionnaire
* Diseases that can modify the dietary regimen (celiac disease, diabetes)
* Diseases that are known to predispose to eoCRC (personal past or recent history of inflammatory bowel disease, past history of pelvic irradiation)
* Unable to give written consents and to fill in the electronic questionnaire
Minimum Eligible Age
18 Years
Maximum Eligible Age
49 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
UNKNOWN
Sponsor Role
collaborator
Ospedale Civile Guglielmo da Saliceto, Piacenza, Italy
UNKNOWN
Sponsor Role
collaborator
Centro di Riferimento Oncologico di Aviano, Aviano, Italy
UNKNOWN
Sponsor Role
collaborator
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
OTHER
Sponsor Role
collaborator
Gastroenterology Unit, University Hospital of Padova, Padova, Italy
UNKNOWN
Sponsor Role
collaborator
Azienda Ospedaliero-Universitaria Careggi
OTHER
Sponsor Role
collaborator
IRCCS Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy
UNKNOWN
Sponsor Role
collaborator
Azienda Ospedaliera San Gerardo di Monza, Monza, Italy
UNKNOWN
Sponsor Role
collaborator
Azienda ULSS5 Polesana, Rovigo, Italy
UNKNOWN
Sponsor Role
collaborator
Istituto Tumori Regina Elena - IRCCS IFO, Roma, Italy
UNKNOWN
Sponsor Role
collaborator
University Hospital of Padova, Padova, Italy
UNKNOWN
Sponsor Role
collaborator
IRCCS De Bellis, Castellana Grotte, Italy
UNKNOWN
Sponsor Role
collaborator
University Hospital HELIOS Klinikum Wuppertal, Center for Hereditary Tumors, University of Witten-Herdecke, Wuppertal, Germany
UNKNOWN
Sponsor Role
collaborator
Hospital of the University of Munich (LMU), Campus Großhadern, Munich, Germany
UNKNOWN
Sponsor Role
collaborator
Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
UNKNOWN
Sponsor Role
collaborator
Helsinki University Hospital, Helsinki, Finland
UNKNOWN
Sponsor Role
collaborator
Oslo University Hospital (OUS), Institute for Cancer Genetics and Informatics Norwegian Radium Hospital, Oslo, Norway
UNKNOWN
Sponsor Role
collaborator
Department of Medicine University of Chicago Medicine, Illinois, USA
UNKNOWN
Sponsor Role
collaborator
University of Colorado Hospital, CO, USA
UNKNOWN
Sponsor Role
collaborator
University of Michigan Ann Arbor, Michigan, USA
UNKNOWN
Sponsor Role
collaborator
Columbia University Irving Medical Center, New York, NY
UNKNOWN
Sponsor Role
collaborator
The James Comprehensive Cancer Center, Columbus, OH, USA
UNKNOWN
Sponsor Role
collaborator
Ohio State University
OTHER
Sponsor Role
collaborator
The Cleveland Clinic
OTHER
Sponsor Role
collaborator
Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia
UNKNOWN
Sponsor Role
collaborator
San Raffaele University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cavestro Giulia Martina MD PhD
Prof Cavestro Giulia Martina
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giulia Martina Cavestro, MD PhD
Role: PRINCIPAL_INVESTIGATOR
IRCCS San Raffaele Scientific Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital
Denver, Colorado, United States
Site Status
RECRUITING
Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine University of Chicago Medicine
Chicago, Illinois, United States
Site Status
RECRUITING
Department of Gastrointestinal Surgery, Helsinki University Hospital
Helsinki, , Finland
Site Status
RECRUITING
Department of General, Visceral and Transplant Surgery, Hospital of the University of Munich (LMU)
Munich, , Germany
Site Status
RECRUITING
Gabriela Moslein
Wuppertal, , Germany
Site Status
RECRUITING
Prof Giulia Martina Cavestro, MD PhD
Milan, Lombardy, Italy
Site Status
RECRUITING
Division of Cancer Medicine, Oslo University Hospital (OUS), Institute for Cancer Genetics and Informatics Norwegian Radium Hospital
Oslo, , Norway
Site Status
RECRUITING
Department of Gastroenterology, Hospital Clínic de Barcelona, University of Barcelona
Barcelona, , Spain
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Finland
Germany
Italy
Norway
Spain
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Russo AG, Andreano A, Sartore-Bianchi A, Mauri G, Decarli A, Siena S. Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. Cancer Epidemiol. 2019 Jun;60:134-140. doi: 10.1016/j.canep.2019.03.015. Epub 2019 Apr 18.
Reference Type
BACKGROUND
Zorzi M, Dal Maso L, Francisci S, Buzzoni C, Rugge M, Guzzinati S; AIRTUM Working Group. Trends of colorectal cancer incidence and mortality rates from 2003 to 2014 in Italy. Tumori. 2019 Oct;105(5):417-426. doi: 10.1177/0300891619838336. Epub 2019 Mar 27.
Reference Type
BACKGROUND
Zorzi M, Cavestro GM, Guzzinati S, Dal Maso L, Rugge M; AIRTUM Working Group. Decline in the incidence of colorectal cancer and the associated mortality in young Italian adults. Gut. 2020 Oct;69(10):1902-1903. doi: 10.1136/gutjnl-2019-320406. Epub 2019 Dec 16. No abstract available.
Reference Type
BACKGROUND
Wang L, Lo CH, He X, Hang D, Wang M, Wu K, Chan AT, Ogino S, Giovannucci EL, Song M. Risk Factor Profiles Differ for Cancers of Different Regions of the Colorectum. Gastroenterology. 2020 Jul;159(1):241-256.e13. doi: 10.1053/j.gastro.2020.03.054. Epub 2020 Apr 1.
Reference Type
BACKGROUND
Zhong Y, Zhu Y, Li Q, Wang F, Ge X, Zhou G, Miao L. Association between Mediterranean diet adherence and colorectal cancer: a dose-response meta-analysis. Am J Clin Nutr. 2020 Jun 1;111(6):1214-1225. doi: 10.1093/ajcn/nqaa083.
Reference Type
BACKGROUND
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732. doi: 10.1038/s41575-019-0189-8. Epub 2019 Aug 27.
Reference Type
BACKGROUND
Tabung FK, Brown LS, Fung TT. Dietary Patterns and Colorectal Cancer Risk: A Review of 17 Years of Evidence (2000-2016). Curr Colorectal Cancer Rep. 2017 Dec;13(6):440-454. doi: 10.1007/s11888-017-0390-5. Epub 2017 Oct 17.
Reference Type
BACKGROUND
Ahnen DJ, Wade SW, Jones WF, Sifri R, Mendoza Silveiras J, Greenamyer J, Guiffre S, Axilbund J, Spiegel A, You YN. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014 Feb;89(2):216-24. doi: 10.1016/j.mayocp.2013.09.006. Epub 2014 Jan 4.
Reference Type
RESULT
Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012 Aug;25(8):1128-39. doi: 10.1038/modpathol.2012.61. Epub 2012 Apr 6.
Reference Type
RESULT
Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, De P, Tervonen H, Walsh PM, Bucher O, Engholm G, Jackson C, McClure C, Woods RR, Saint-Jacques N, Morgan E, Ransom D, Thursfield V, Moller B, Leonfellner S, Guren MG, Bray F, Arnold M. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):511-518. doi: 10.1016/S2468-1253(19)30147-5. Epub 2019 May 16.
Reference Type
RESULT
Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis-Ribeiro M, Bento MJ, Zadnik V, Pellise M, Esteban L, Kaminski MF, Suchanek S, Ngo O, Majek O, Leja M, Kuipers EJ, Spaander MC. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut. 2019 Oct;68(10):1820-1826. doi: 10.1136/gutjnl-2018-317592. Epub 2019 May 16.
Reference Type
RESULT
Siegel RL, Torre LA, Soerjomataram I, Hayes RB, Bray F, Weber TK, Jemal A. Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019 Dec;68(12):2179-2185. doi: 10.1136/gutjnl-2019-319511. Epub 2019 Sep 5.
Reference Type
RESULT
Khan NA, Hussain M, ur Rahman A, Farooqui WA, Rasheed A, Memon AS. Dietary Practices, Addictive Behavior and Bowel Habits and Risk of Early Onset Colorectal Cancer: a Case Control Study. Asian Pac J Cancer Prev. 2015;16(17):7967-73. doi: 10.7314/apjcp.2015.16.17.7967.
Reference Type
RESULT
Song M, Chan AT. Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention. Clin Gastroenterol Hepatol. 2019 Jan;17(2):275-289. doi: 10.1016/j.cgh.2018.07.012. Epub 2018 Jul 18.
Reference Type
RESULT
Nimptsch K, Malik VS, Fung TT, Pischon T, Hu FB, Willett WC, Fuchs CS, Ogino S, Chan AT, Giovannucci E, Wu K. Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women. Int J Cancer. 2014 May 15;134(10):2458-67. doi: 10.1002/ijc.28578. Epub 2013 Nov 25.
Reference Type
RESULT
Garcia-Larsen V, Morton V, Norat T, Moreira A, Potts JF, Reeves T, Bakolis I. Dietary patterns derived from principal component analysis (PCA) and risk of colorectal cancer: a systematic review and meta-analysis. Eur J Clin Nutr. 2019 Mar;73(3):366-386. doi: 10.1038/s41430-018-0234-7. Epub 2018 Jul 26.
Reference Type
RESULT
Jones P, Cade JE, Evans CEL, Hancock N, Greenwood DC. The Mediterranean diet and risk of colorectal cancer in the UK Women's Cohort Study. Int J Epidemiol. 2017 Dec 1;46(6):1786-1796. doi: 10.1093/ije/dyx155.
Reference Type
RESULT
Castello A, Amiano P, Fernandez de Larrea N, Martin V, Alonso MH, Castano-Vinyals G, Perez-Gomez B, Olmedo-Requena R, Guevara M, Fernandez-Tardon G, Dierssen-Sotos T, Llorens-Ivorra C, Huerta JM, Capelo R, Fernandez-Villa T, Diez-Villanueva A, Urtiaga C, Castilla J, Jimenez-Moleon JJ, Moreno V, Davila-Batista V, Kogevinas M, Aragones N, Pollan M; MCC-Spain researchers. Low adherence to the western and high adherence to the mediterranean dietary patterns could prevent colorectal cancer. Eur J Nutr. 2019 Jun;58(4):1495-1505. doi: 10.1007/s00394-018-1674-5. Epub 2018 Mar 26.
Reference Type
RESULT
Agnoli C, Grioni S, Sieri S, Palli D, Masala G, Sacerdote C, Vineis P, Tumino R, Giurdanella MC, Pala V, Berrino F, Mattiello A, Panico S, Krogh V. Italian Mediterranean Index and risk of colorectal cancer in the Italian section of the EPIC cohort. Int J Cancer. 2013 Mar 15;132(6):1404-11. doi: 10.1002/ijc.27740. Epub 2012 Aug 7.
Reference Type
RESULT
Rosato V, Bosetti C, Levi F, Polesel J, Zucchetto A, Negri E, La Vecchia C. Risk factors for young-onset colorectal cancer. Cancer Causes Control. 2013 Feb;24(2):335-41. doi: 10.1007/s10552-012-0119-3. Epub 2012 Dec 8.
Reference Type
RESULT
Liu PH, Wu K, Ng K, Zauber AG, Nguyen LH, Song M, He X, Fuchs CS, Ogino S, Willett WC, Chan AT, Giovannucci EL, Cao Y. Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women. JAMA Oncol. 2019 Jan 1;5(1):37-44. doi: 10.1001/jamaoncol.2018.4280.
Reference Type
RESULT
Nguyen LH, Liu PH, Zheng X, Keum N, Zong X, Li X, Wu K, Fuchs CS, Ogino S, Ng K, Willett WC, Chan AT, Giovannucci EL, Cao Y. Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer. JNCI Cancer Spectr. 2018 Nov;2(4):pky073. doi: 10.1093/jncics/pky073. Epub 2019 Jan 25.
Reference Type
RESULT
Kim JY, Jung YS, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Choi KY, Park DI. Different risk factors for advanced colorectal neoplasm in young adults. World J Gastroenterol. 2016 Apr 7;22(13):3611-20. doi: 10.3748/wjg.v22.i13.3611.
Reference Type
RESULT
Gausman V, Dornblaser D, Anand S, Hayes RB, O'Connell K, Du M, Liang PS. Risk Factors Associated With Early-Onset Colorectal Cancer. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2752-2759.e2. doi: 10.1016/j.cgh.2019.10.009. Epub 2019 Oct 14.
Reference Type
RESULT
Low EE, Demb J, Liu L, Earles A, Bustamante R, Williams CD, Provenzale D, Kaltenbach T, Gawron AJ, Martinez ME, Gupta S. Risk Factors for Early-Onset Colorectal Cancer. Gastroenterology. 2020 Aug;159(2):492-501.e7. doi: 10.1053/j.gastro.2020.01.004. Epub 2020 Jan 9.
Reference Type
RESULT
Kim NH, Jung YS, Yang HJ, Park SK, Park JH, Park DI, Sohn CI. Prevalence of and Risk Factors for Colorectal Neoplasia in Asymptomatic Young Adults (20-39 Years Old). Clin Gastroenterol Hepatol. 2019 Jan;17(1):115-122. doi: 10.1016/j.cgh.2018.07.011. Epub 2018 Jul 17.
Reference Type
RESULT
Zheng X, Hur J, Nguyen LH, Liu J, Song M, Wu K, Smith-Warner SA, Ogino S, Willett WC, Chan AT, Giovannucci E, Cao Y. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer. J Natl Cancer Inst. 2021 May 4;113(5):543-552. doi: 10.1093/jnci/djaa164.
Reference Type
RESULT
Slimani N, Ferrari P, Ocke M, Welch A, Boeing H, Liere M, Pala V, Amiano P, Lagiou A, Mattisson I, Stripp C, Engeset D, Charrondiere R, Buzzard M, Staveren W, Riboli E. Standardization of the 24-hour diet recall calibration method used in the european prospective investigation into cancer and nutrition (EPIC): general concepts and preliminary results. Eur J Clin Nutr. 2000 Dec;54(12):900-17. doi: 10.1038/sj.ejcn.1601107.
Reference Type
RESULT
Slimani N, Kaaks R, Ferrari P, Casagrande C, Clavel-Chapelon F, Lotze G, Kroke A, Trichopoulos D, Trichopoulou A, Lauria C, Bellegotti M, Ocke MC, Peeters PH, Engeset D, Lund E, Agudo A, Larranaga N, Mattisson I, Andren C, Johansson I, Davey G, Welch AA, Overvad K, Tjonneland A, Van Staveren WA, Saracci R, Riboli E. European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study: rationale, design and population characteristics. Public Health Nutr. 2002 Dec;5(6B):1125-45. doi: 10.1079/PHN2002395.
Reference Type
RESULT
Cavestro GM, Mannucci A, Zuppardo RA, Di Leo M, Stoffel E, Tonon G. Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features. Dig Liver Dis. 2018 Jun;50(6):521-532. doi: 10.1016/j.dld.2018.02.009. Epub 2018 Feb 23.
Reference Type
RESULT
Puzzono M, Mannucci A, Granno S, Zuppardo RA, Galli A, Danese S, Cavestro GM. The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review. Cancers (Basel). 2021 Nov 25;13(23):5933. doi: 10.3390/cancers13235933.
Reference Type
RESULT
Cavestro GM, Mannucci A, Balaguer F, Hampel H, Kupfer SS, Repici A, Sartore-Bianchi A, Seppala TT, Valentini V, Boland CR, Brand RE, Buffart TE, Burke CA, Caccialanza R, Cannizzaro R, Cascinu S, Cercek A, Crosbie EJ, Danese S, Dekker E, Daca-Alvarez M, Deni F, Dominguez-Valentin M, Eng C, Goel A, Guillem JG, Houwen BBSL, Kahi C, Kalady MF, Kastrinos F, Kuhn F, Laghi L, Latchford A, Liska D, Lynch P, Malesci A, Mauri G, Meldolesi E, Moller P, Monahan KJ, Moslein G, Murphy CC, Nass K, Ng K, Oliani C, Papaleo E, Patel SG, Puzzono M, Remo A, Ricciardiello L, Ripamonti CI, Siena S, Singh SK, Stadler ZK, Stanich PP, Syngal S, Turi S, Urso ED, Valle L, Vanni VS, Vilar E, Vitellaro M, You YN, Yurgelun MB, Zuppardo RA, Stoffel EM; Associazione Italiana Familiarita Ereditarieta Tumori; Collaborative Group of the Americas on Inherited Gastrointestinal Cancer; European Hereditary Tumour Group, and the International Society for Gastrointestinal Hereditary Tumours. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines. Clin Gastroenterol Hepatol. 2023 Mar;21(3):581-603.e33. doi: 10.1016/j.cgh.2022.12.006. Epub 2022 Dec 20.
Reference Type
RESULT
Related Links
Access external resources that provide additional context or updates about the study.
http://www.fondazione-menarini.it/Home/Eventi/Early-onset-Colorectal-Cancer/813/Presentazione
Early onset colorectal cancer, first international scientific meeting
https://www.youtube.com/watch?v=JlpciBBFg5k
Video interview on the early onset colorectal cancer
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DEMETRA2020.0001
Identifier Type: -
Identifier Source: org_study_id